ArticleBlood advances2024
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 59 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TECLIMMY1001-P3: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Who cites it
59 citing papers in PubMed, 5 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- [Vaccination of immunocompromised individuals: Expert opinion - update 2026].Wiener klinische Wochenschrift · 2026Guideline
- Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review.Annals of hematology · 2026Pooled it
- Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence.Frontiers in immunology · 2026Pooled it
- Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies.Annals of hematology · 2025Pooled it
- To substitute or not? A systematic review of immunoglobulin replacement therapy in multiple myeloma patients treated with bispecific antibodies.Frontiers in immunology · 2025Pooled it
- Trial
- Trial
- Article
- Transition from inpatient to outpatient step-up dosing of bispecific antibodies in multiple myeloma: real-world insights.Blood advances · 2026Article
- Reduced Pathogen-Specific T Cell Response With BCMA-Targeted T Cell-Engaging Therapy to Multiple Myeloma.EJHaem · 2026Article
- Real World Data and Its Impact on the Management of Plasma Cell Dyscrasias.Current hematologic malignancy reports · 2026Review
- Mitigating Teclistamab Toxicity: Prophylactic Tocilizumab and Timing of Immunoglobulin Replacement Therapy in a Nationwide Cohort.American journal of hematology · 2026Article
- Article
- Epidemiology and Risk Factors for Infection in Multiple Myeloma Patients Treated With Bispecific Antibodies.Open forum infectious diseases · 2026Article
- Anti-BCMA immunotherapies deplete plasmacytoid dendritic cells and impair antiviral immunity in multiple myeloma.HemaSphere · 2026Article
- Mechanistic modeling of FcRn-dependent IgG drug interactions: Clinical applications and dosing implications.Journal of pharmacokinetics and pharmacodynamics · 2026Article
- Late-onset progressive multifocal leukoencephalopathy after teclistamab in multiple myeloma: extending the timeline of infectious risk.Haematologica · 2026Article
- Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.Blood advances · 2026Article
- Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for multiple myeloma.Blood advances · 2026Article
- Analyzing Real-World Infection Risk in Multiple Myeloma Patients Receiving Teclistamab.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 10 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractTeclistamab and other B-cell maturation antigen (BCMA)-targeting bispecific antibodies (BsAbs) have substantial activity in patients with heavily pretreated multiple myeloma (MM) but are associated with a high rate of infections. BCMA is also expressed on normal plasma cells and mature B cells, which are essential for the generation of a humoral immune response. The aim of this study was to improve the understanding of the impact of BCMA-targeting BsAbs on humoral immunity. The impact of teclistamab on polyclonal immunoglobulins and B cell counts was evaluated in patients with MM who received once-weekly teclistamab 1.5 mg/kg subcutaneously. Vaccination responses were assessed in a subset of patients. Teclistamabinduced rapid depletion of peripheral blood B cells in patients with MM and eliminated normal plasma cells in ex vivo assays. In addition, teclistamab reduced the levels of polyclonal immunoglobulins (immunoglobulin G [IgG], IgA, IgE, and IgM), without recovery over time while receiving teclistamab therapy. Furthermore, response to vaccines against Streptococcus pneumoniae, Haemophilus influenzae type B, and severe acute respiratory syndrome coronavirus 2 was severely impaired in patients treated with teclistamab compared with vaccination responses observed in patients with newly diagnosed MM or relapsed/refractory MM. Intravenous immunoglobulin (IVIG) use was associated with a significantly lower risk of serious infections among patients treated with teclistamab (cumulative incidence of infections at 6 months: 5.3% with IVIG vs 54.8% with observation only [P < .001]). In conclusion, our data show severe defects in humoral immunity induced by teclistamab, the impact of which can be mitigated by the use of immunoglobulin supplementation. This trial was registered at www.ClinicalTrials.gov as #NCT04557098.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.